Organon & Co 2022 SR
The report highlights Organon's first full year of operations, focusing on its 'Her Promise' ESG strategy. Key achievements include completing five business development deals in women's health and reaching nearly half of its goal to prevent 120 million unplanned pregnancies by 2030. The company maintained the most gender-diverse board in the S&P 500 and achieved over 99% pay equity in major markets. Environmentally, Organon reduced Scope 1 and 2 emissions by 3.4% from a 2020 baseline and integrated its inaugural TCFD disclosure.
Company: Organon & Co
Sector: Health Care
Country: United States
Year: 2022
Type: SR
Pages: 133
Organon & Co
ESG Report
The report highlights Organon's first full year of operations, focusing on its 'Her Promise' ESG strategy. Key achievements include completing five business development deals in women's health and reaching nearly half of its goal to prevent 120 million unplanned pregnancies by 2030. The company maintained the most gender-diverse board in the S&P 500 and achieved over 99% pay equity in major markets. Environmentally, Organon reduced Scope 1 and 2 emissions by 3.4% from a 2020 baseline and integrated its inaugural TCFD disclosure.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2022
Reporting Period
Jan 1, 2022 - Dec 31, 2022
Fiscal Year
2022
Published
Jun 1, 2023
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Sustainable Development Goals
Other Standards
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Scope 3:
Energy Consumption
Water Consumption
Total Waste
Women on Board
Women in Management
Workplace Fatalities
Employees